Axsome Therapeutics, Inc. (AXSM) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
AXSM Revenue Growth
Revenue Breakdown (FY 2025)
AXSM's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
AXSM Revenue Analysis (2014–2025)
As of May 6, 2026, Axsome Therapeutics, Inc. (AXSM) generated trailing twelve-month (TTM) revenue of $708.2 million, reflecting explosive growth of +57.4% year-over-year. The most recent quarter (Q1 2026) recorded $191.2 million in revenue, down 2.4% sequentially.
Looking at the longer-term picture, AXSM's historical revenue data shows a 3-year CAGR of +133.7%. The company achieved its highest annual revenue of $638.5 million in 2025, representing a new all-time high.
Revenue diversification analysis shows AXSM's business is primarily driven by Product (100%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including INVA (+13.6% YoY), SUPN (+16.3% YoY), and ACAD (+11.9% YoY), AXSM has outperformed the peer group in terms of revenue growth. Compare AXSM vs INVA →
AXSM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AXSMCurrent | $708M | +57.4% | - | -26.5% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 ACAD | $1.1B | +11.9% | +19.4% | 9.8% | |
 INTR | $9.7B | - | - | 12.4% |
AXSM Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $638.5M | +65.5% | $591.0M | 92.6% | $-169,235,000 | -26.5% |
| 2024 | $385.7M | +42.5% | $352.4M | 91.4% | $-280,562,000 | -72.7% |
| 2023 | $270.6M | +440.8% | $244.5M | 90.4% | $-231,825,000 | -85.7% |
| 2022 | $50.0M | - | $44.8M | 89.6% | $-179,799,000 | -359.3% |
| 2021 | $0 | - | $0 | - | $-124,707,000 | - |
| 2020 | $0 | - | $0 | - | $-99,141,328 | - |
| 2019 | $0 | - | $-37,330 | - | $-67,245,097 | - |
| 2018 | $0 | - | $-48,935 | - | $-32,846,577 | - |
| 2017 | $0 | - | $-42,557 | - | $-27,164,307 | - |
| 2016 | $0 | - | $-20,484 | - | $-27,543,508 | - |
Full AXSM Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See AXSM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AXSM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AXSM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAXSM — Frequently Asked Questions
Quick answers to the most common questions about buying AXSM stock.
Is AXSM's revenue growth accelerating or slowing?
AXSM revenue is accelerating at +57.4% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $708M. Growth momentum has increased versus prior periods.
What is AXSM's long-term revenue growth rate?
Axsome Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +57.4% is above this long-term average.
How is AXSM's revenue distributed by segment?
AXSM reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.